Enveda Raises $311M for AI Drug Discovery

Enveda has raised one of the largest recent rounds in AI drug discovery as it pushes more nature-derived candidates into human trials.

What happened

The company raised a $311M Series E at a $2B valuation. Enveda uses AI to search plants and microbes for molecules that could become drug candidates, combining computational discovery with wet-lab validation.

The company already has multiple AI-discovered programmes in human clinical trials and plans to use the new capital to expand its pipeline and accelerate development.

Why it matters

AI drug discovery is entering a more demanding phase. Training models and identifying promising molecules is only the first step; the real test is whether those candidates can survive clinical development.

Enveda is notable because it is already moving beyond discovery into human testing, where biological complexity and regulatory scrutiny become much harder to abstract away.

The bigger picture

The strongest AI-biotech companies may increasingly be judged less on model novelty and more on proprietary data, wet-lab execution and clinical progress. Capital is concentrating around platforms that can show the full path from computation to therapeutics.